Effects of recombinant human extracellular-superoxide dismutase type C on myocardial infarct size in pigs.
The efficacy of human extracellular-superoxide dismutase type C (EC-SOD C) to limit infarct size after ischemia and reperfusion was explored and compared to that of EC-SOD C combined with catalase (CAT) and to that of CAT alone. EC-SOD C binds to heparan sulphate proteoglycan on the cell surfaces. Thirty-two pigs were subjected to 45 min of myocardial ischemia followed by 4 h of reperfusion. Control pigs (group A; n = 8) received 300 mL of saline into the great cardiac vein during a 30-min period started 5 min prior to reperfusion; pigs in group B (EC-SOD C; n = 8) got 16.6 mg of EC-SOD C; pigs in group C (EC-SOD C + CAT; n = 8) got 16.6 mg of EC-SOD C together with 150 mg of CAT. Pigs in group D (CAT; n = 8) received 150 mg of CAT. In groups B, C, and D, the drug was dissolved in saline and infused into the great cardiac. Infarct size expressed as percent of area at risk was smaller in groups B (14.5 +/- 16.7%) and C (40.8 +/- 13.3%) than in groups A (78.8 +/- 8.6%) and D (67.2 +/- 18.6%; p less than .05). Creatine kinase (CK) activity in ischemic myocardium was higher in groups B (1740 +/- 548 U/g) and C (1729 +/- 358 U/g) than in groups A (1184 +/- 237 U/g) and D (1251 +/- 434 U/g; p less than .05). There was an inverse relation (r = -.83) between infarct size and CK content. The EC-SOD C infusions resulted in only minimal increases in plasma SOD activities. In conclusion, the presence of SOD on the cell surfaces is of importance in the prevention of reperfusion injury rather than circulating SOD.
Hatori
N
N
Department of Cardiology, Karolinska Hospital, Stockholm, Sweden.
Sjöquist
P O
PO
Marklund
S L
SL
Rydén
L
L
D000818:Animals; D003402:Creatine Kinase / Q000378:metabolism; D005260:Female; D006439:Hemodynamics; D008297:Male; D009203:Myocardial Infarction / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control; D015428:Myocardial Reperfusion Injury / Q000150:complications* / Q000503:physiopathology; D011994:Recombinant Proteins / Q000494:pharmacology; D013482:Superoxide Dismutase / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D013552:Swine; D016277:Ventricular Function, Left
D011994:Recombinant Proteins; D013482:Superoxide Dismutase; D003402:Creatine Kinase